442 related articles for article (PubMed ID: 22122561)
1. Comparison of risk of malignancy index (RMI), CA125, CA 19-9, ultrasound score, and menopausal status in borderline ovarian tumor.
Alanbay I; Akturk E; Coksuer H; Ercan M; Karaşahin E; Dede M; Yenen MC; Ozan H; Baser I
Gynecol Endocrinol; 2012 Jun; 28(6):478-82. PubMed ID: 22122561
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors.
Zhang S; Yu S; Hou W; Li X; Ning C; Wu Y; Zhang F; Jiao YF; Lee LTO; Sun L
J Ovarian Res; 2019 Sep; 12(1):87. PubMed ID: 31526390
[TBL] [Abstract][Full Text] [Related]
3. Comparison of risk of malignancy indices; RMI 1-4 in borderline ovarian tumor.
Yenen MC; Alanbay I; Aktürk E; Ercan CM; Coksuer H; Karaşahin E; Ozan H; Dede M
Eur J Gynaecol Oncol; 2012; 33(2):168-73. PubMed ID: 22611957
[TBL] [Abstract][Full Text] [Related]
4. Risk for malignant and borderline ovarian neoplasms following basic preoperative evaluation by ultrasonography, ca125 level and age.
Karadag B; Kocak M; Kayikcioglu F; Ercan F; Dilbaz B; Kose M; Haberal A
Asian Pac J Cancer Prev; 2014; 15(19):8489-93. PubMed ID: 25339052
[TBL] [Abstract][Full Text] [Related]
5. Pre-operative evaluation of ovarian tumors by risk of malignancy index, CA125 and ultrasound.
Arun-Muthuvel V; Jaya V
Asian Pac J Cancer Prev; 2014; 15(6):2929-32. PubMed ID: 24761927
[TBL] [Abstract][Full Text] [Related]
6. Comparison of ultrasound score, CA125, menopausal status, and risk of malignancy index in differentiating between benign and borderline or malignant ovarian tumors.
Leelahakorn S; Tangjitgamol S; Manusirivithaya S; Thongsuksai P; Jaroenchainon P; Jivangkul C
J Med Assoc Thai; 2005 Oct; 88 Suppl 2():S22-30. PubMed ID: 17718292
[TBL] [Abstract][Full Text] [Related]
7. Risk of malignancy index in preoperative evaluation of pelvic masses.
Ashrafgangooei T; Rezaeezadeh M
Asian Pac J Cancer Prev; 2011; 12(7):1727-30. PubMed ID: 22126553
[TBL] [Abstract][Full Text] [Related]
8. The risk of malignancy index in discrimination of adnexal masses.
Ulusoy S; Akbayir O; Numanoglu C; Ulusoy N; Odabas E; Gulkilik A
Int J Gynaecol Obstet; 2007 Mar; 96(3):186-91. PubMed ID: 17280665
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses.
Morgante G; la Marca A; Ditto A; De Leo V
Br J Obstet Gynaecol; 1999 Jun; 106(6):524-7. PubMed ID: 10426607
[TBL] [Abstract][Full Text] [Related]
10. Comparison of four malignancy risk indices in the preoperative evaluation of patients with pelvic masses.
Yamamoto Y; Yamada R; Oguri H; Maeda N; Fukaya T
Eur J Obstet Gynecol Reprod Biol; 2009 Jun; 144(2):163-7. PubMed ID: 19327881
[TBL] [Abstract][Full Text] [Related]
11. A prospective study to evaluate the risk malignancy index and its diagnostic implication in patients with suspected ovarian mass.
Dora SK; Dandapat AB; Pande B; Hota JP
J Ovarian Res; 2017 Aug; 10(1):55. PubMed ID: 28806987
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses.
Tingulstad S; Hagen B; Skjeldestad FE; Onsrud M; Kiserud T; Halvorsen T; Nustad K
Br J Obstet Gynaecol; 1996 Aug; 103(8):826-31. PubMed ID: 8760716
[TBL] [Abstract][Full Text] [Related]
13. [The estimation of the probability of tumor malignacy on the basis of test combination in the primary diagnosis of adnexal tumors].
Smoleń A; Stachowicz N; Czekierowski A; Kotarski J
Ginekol Pol; 2010 Apr; 81(4):254-61. PubMed ID: 20476596
[TBL] [Abstract][Full Text] [Related]
14. External validation of the adapted Risk of Malignancy Index incorporating tumor size in the preoperative evaluation of adnexal masses.
van den Akker PA; Zusterzeel PL; Aalders AL; Snijders MP; Samlal RA; Vollebergh JH; Kluivers KB; Massuger LF
Eur J Obstet Gynecol Reprod Biol; 2011 Dec; 159(2):422-5. PubMed ID: 21824712
[TBL] [Abstract][Full Text] [Related]
15. Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass.
Håkansson F; Høgdall EV; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Høgdall C;
Acta Obstet Gynecol Scand; 2012 Apr; 91(4):496-502. PubMed ID: 22229703
[TBL] [Abstract][Full Text] [Related]
16. A risk of malignancy index in preoperative diagnosis of ovarian cancer.
Ma S; Shen K; Lang J
Chin Med J (Engl); 2003 Mar; 116(3):396-9. PubMed ID: 12781045
[TBL] [Abstract][Full Text] [Related]
17. Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis?
Song T; Lee DH; Jung YW; Yun BS; Seong SJ; Choi CH; Lee JW; Bae DS; Kim BG
Gynecol Obstet Invest; 2018; 83(1):45-51. PubMed ID: 28571024
[TBL] [Abstract][Full Text] [Related]
18. [Ovarian tumor markers of presumed benign ovarian tumors].
Lahlou N; Brun JL
J Gynecol Obstet Biol Reprod (Paris); 2013 Dec; 42(8):752-9. PubMed ID: 24210243
[TBL] [Abstract][Full Text] [Related]
19. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the importance of the serum levels of CA-125, CA15-3, CA-19-9, carcinoembryonic antigen and alpha fetoprotein for distinguishing benign and malignant adnexal masses and contribution of different test combinations to diagnostic accuracy.
Bozkurt M; Yumru AE; Aral I
Eur J Gynaecol Oncol; 2013; 34(6):540-4. PubMed ID: 24601047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
